Source: Mary Cornatzer, NEWS & OBSERVER, 9/7/11

It took some wooing, but Pfizer was finally able to convince Icagen shareholders that its $56 million offer for Icagen was a good deal. The companies announced Tuesday morning that enough shareholders had tendered their shares for the acquisition to go through.

For more of this story, click here.